Viking Therapeutics is having a banner year, delivering more than 200% returns to shareholders. But a recent dip of more than 10% has analysts questioning whether the stock is really a good investment. What’s going on with Viking, and should you buy the dip or let this one pass you by?
What Is VK 2735?
Nearly everyone has heard of Ozempic, the incredibly popular weight loss drug manufactured by Novo Nordisk. But the market for weight loss medications is so big that a lot of areas are experiencing shortages. This indicates that there’s still plenty of room for competition, and Viking has responded with a similar medication currently known as VK 2735. While the drug is still in clinical trials, some analysts believe it has the potential to achieve sales of $21 billion per year once approved.
Proceed With Caution
Despite having a potential blockbuster on its hands, Viking is currently surprisingly volatile. The recent dip was caused by a head-scratching selloff that followed an update on one of the company’s other clinical trials. That update, which was on a potential hepatitis treatment, actually yielded good news: the drug is ready to move into a later-stage trial. But its commercial value may be limited, as existing medications may already serve the same purpose.
Still, that’s no reason for a selloff. Instead, analysts believe that day traders may be driving Viking’s short-term prospects. As clinical data comes in, the stock is likely to rise and fall based solely on that immediate information, rather than a longer-range view. If you’re a long-term investor who’s willing to ride the wave in hopes of an immense payout on the weight loss drug, this could be a great buy. But it’s definitely not a good choice for the faint of heart or those hoping for a quick return.
Neither Stocks.News nor Lisa Fritscher has positions in any of the stocks mentioned.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned thru out the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
Contributing Writer
Lisa Fritscher has been a contributing writer for App.Stock.News since 2024. Lisa has been interested in investing since winning The Stock Market Game in high school. In more than a decade as a professional writer, she has written consumer-facing financial information and advice articles for a wide variety of publications. She has a Bachelor of Arts in Psychology from the University of South Flori...